Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IBI351 plus chemotherapy for KRAS G12C-mutant advanced or metastatic non-squamous non-small cell lung cancer
CTR20221975Phase 3Active
- Sponsor
- InnoCare Pharma
- Start
- Sep 2022
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of fulzerasib in Non-small cell lung cancer (NS-NSCLC), sponsored by InnoCare Pharma. Started Sep 2022; status: active.
02
Drugs
fulzerasib
03
Conditions
Non-small cell lung cancer (NS-NSCLC)
Beyond the preview
Go deeper on CTR20221975.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20221975.